Estadístiques de Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Visites totals
views | |
---|---|
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up | 116 |
Visites totals per mes
views | |
---|---|
October 2024 | 0 |
November 2024 | 0 |
December 2024 | 0 |
January 2025 | 0 |
February 2025 | 1 |
March 2025 | 0 |
April 2025 | 0 |
Visites al fitxer
views | |
---|---|
fradet-aoo-rand.pdf(legacy) | 116 |
fradet-aoo-rand.pdf | 26 |
Vistes principals per país
views | |
---|---|
United States | 71 |
China | 8 |
Sweden | 8 |
Germany | 5 |
Spain | 3 |
France | 3 |
Serbia | 3 |
Australia | 2 |
Canada | 2 |
Iran | 2 |
South Korea | 2 |
Argentina | 1 |
Brazil | 1 |
Czechia | 1 |
Greece | 1 |
Ireland | 1 |
Malaysia | 1 |
Russia | 1 |
Visites principals per ciutat
views | |
---|---|
San Ramon | 25 |
Shenzhen | 8 |
Boardman | 6 |
Ann Arbor | 5 |
Fairfield | 5 |
Mountain View | 5 |
Ashburn | 3 |
Barcelona | 3 |
San Mateo | 3 |
Subotica | 3 |
Daejeon | 2 |
Toronto | 2 |
Braunschweig | 1 |
Cambridge | 1 |
Carapicuíba | 1 |
Dearborn | 1 |
Dublin | 1 |
Leawood | 1 |
Maryborough | 1 |
Menlo Park | 1 |
Patras | 1 |
Pinjarra | 1 |
Resistencia | 1 |
Ridge | 1 |
San Diego | 1 |
Shah Alam | 1 |
Tustin | 1 |